Publications by authors named "Thorsten Goetze"

Claim this Profile
A
A First-in-Class mAb (BI-1607) Targeting FcγRIIB: Preclinical Data and First-in-Human Studies in Patients with HER2-Positive Advanced Solid Tumors.
Javier Cortés, Araceli Priego, Elena Garralda, Katerin Rojas, Simon R Lord, Thorsten O Goetze

Clin Cancer Res· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Perioperative pembrolizumab, trastuzumab and FLOT in HER2-positive localized esophagogastric adenocarcinoma: a phase 2 trial.
Alexander Stein, Eray Goekkurt, Salah-Eddin Al-Batran, Nicolas Moosmann, Thomas J Ettrich, Thorsten Goetze

Nat Med· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment landscape from first- to third-line therapy and quality of life data of patients with pancreatic cancer from the prospective German PARAGON (Platform for Outcome, Quality of Life, and Translational Research on Pancreatic Cancer) registry (IKF-PARAGON study).
Thorsten O Goetze, Salah-Eddin Al-Batran, Ruediger Liersch, Lars Scheuer, Thomas Goehler

Int J Cancer· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Individually compounded multi-chamber vs. standardized parenteral nutrition bags in solid tumors-A randomized clinical trial (IKF-010).
Thorsten Oliver Goetze, Ralf-Dieter Hofheinz, Ingeborg Roetzer, Wolfgang Blau, Thomas Zander

Clin Nutr ESPEN· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Response to the Letter to the Editor: Critical appraisal of the IKF-010 trial.
Salah-Eddin Al-Batran, Thorsten Oliver Goetze, Georg Martin Haag

Clin Nutr ESPEN· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neoadjuvant treatment for incidental gallbladder cancer: A systematic review.
Peeyush Varshney, Saphalta Baghmar, Bhawna Sirohi, Ghassan K Abou-Alfa, Hop Tran Cao, Thorsten Goetze

Ann Hepatobiliary Pancreat Surg· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A plain language summary of NALIRIFOX compared with nab-paclitaxel and gemcitabine for patients with metastatic pancreatic cancer (NAPOLI 3).
Zev A Wainberg, Davide Melisi, Teresa Macarulla, Roberto Pazo Cid, Sreenivasa R Chandana, Thorsten O Goetze

Future Oncol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oligometastatic disease - a renaissance for surgery?
Thorsten Goetze, Mickael Chevallay, Michel Dosch, Jordan Marcelis, Salah-Eddin Al-Batran

Innov Surg Sci· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Paclitaxel/Ramucirumab versus Paclitaxel in 2nd-Line Therapy of Advanced Esophageal Squamous Cell Carcinoma: Randomized Phase II IKF-AIO-RAMOS Trial.
Magdalena K Scheck, Thorsten O Goetze, Thomas J Ettrich, Harald Schmalenberg, Michael Clemens

Oncol Res Treat· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nanoliposomal Irinotecan With Fluorouracil and Leucovorin or Gemcitabine Plus Cisplatin in Advanced Cholangiocarcinoma: A Phase II Study of the AIO Hepatobiliary-YMO Cancer Groups (NIFE-AIO-YMO HEP-0315).
Thomas J Ettrich, Dominik P Modest, Marianne Sinn, Jana K Striefler, Bernhard Opitz, Thorsten Goetze

J Clin Oncol· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of ramucirumab combination chemotherapy as second-line treatment in patients with advanced adenocarcinoma of the stomach or gastroesophageal junction after exposure to checkpoint inhibitors and chemotherapy as first-line therapy.
Michael Masetti, Salah-Eddin Al-Batran, Thorsten O Goetze, Peter Thuss-Patience, Jorge Riera Knorrenschild

Int J Cancer· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adjuvant Gemcitabine Versus Neoadjuvant/Adjuvant FOLFIRINOX in Resectable Pancreatic Cancer: The Randomized Multicenter Phase II NEPAFOX Trial.
Thorsten O Goetze, Alexander Reichart, Ulli S Bankstahl, Claudia Pauligk, Maria Loose

Ann Surg Oncol· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
ADJUBIL: phase II study of adjuvant immunotherapy with STRIDE regimen with/without capecitabine in biliary tract cancers.
Thorsten Goetze, Maria A Gonzalez-Carmona, Lisa Kochen, Nihat Bugra Agaoglu, Salah-Eddin Al-Batran

Future Oncol· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Ramucirumab beyond progression plus TAS-102 in patients with advanced or metastatic esophagogastric adenocarcinoma, after treatment failure on a ramucirumab-based therapy.
Thorsten Oliver Goetze, Alexander Stein, Sylvie Lorenzen, Timorshah Habibzada, Eray Goekkurt

Int J Cancer· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Colorectal Cancer Organoid-Stroma Biobank Allows Subtype-Specific Assessment of Individualized Therapy Responses.
Henner F Farin, Mohammed H Mosa, Benardina Ndreshkjana, Britta M Grebbin, Birgit Ritter, Thorsten O Goetze

Cancer Discov· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial.
Zev A Wainberg, Davide Melisi, Teresa Macarulla, Roberto Pazo Cid, Sreenivasa R Chandana, Thorsten O Goetze

Lancet· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Corrigendum to "Dissecting the genetic heterogeneity of gastric cancer".
Timo Hess, Carlo Maj, Jan Gehlen, Oleg Borisov, Stephan L Haas, Thorsten Oliver Goetze

EBioMedicine· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I/II trial of a peptide-based COVID-19 T-cell activator in patients with B-cell deficiency.
Jonas S Heitmann, Claudia Tandler, Maddalena Marconato, Annika Nelde, Timorshah Habibzada, Thorsten O Goetze

Nat Commun· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Perioperative FLOT plus ramucirumab for resectable esophagogastric adenocarcinoma: A randomized phase II/III trial of the German AIO and Italian GOIM.
Thorsten O Goetze, Ralf-Dieter Hofheinz, Timo Gaiser, Harald Schmalenberg, Dirk Strumberg

Int J Cancer· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dissecting the genetic heterogeneity of gastric cancer.
Timo Hess, Carlo Maj, Jan Gehlen, Oleg Borisov, Stephan L Haas, Thorsten Oliver Goetze

EBioMedicine· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Ramucirumab plus irinotecan / leucovorin / 5-FU versus ramucirumab plus paclitaxel in patients with advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction, who failed one prior line of palliative chemotherapy: the phase II/III RAMIRIS study (AIO-STO-0415).
Sylvie Lorenzen, Alix Schwarz, Claudia Pauligk, Eray Goekkurt, Gertraud Stocker, Thorsten Oliver Goetze

BMC Cancer· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Physiologic Cyclical Load on Inguinal Hernia Scaffold ProFlor Turns Biological Response into Tissue Regeneration.
Giuseppe Amato, Roberto Puleio, Giorgio Romano, Pietro Giorgio Calò, Giuseppe Di Buono, Thorsten Goetze

Biology (Basel)· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dynamic Responsive Inguinal Scaffold Activates Myogenic Growth Factors Finalizing the Regeneration of the Herniated Groin.
Giuseppe Amato, Giorgio Romano, Vito Rodolico, Roberto Puleio, Pietro Giorgio Calò, Thorsten Oliver Goetze

J Funct Biomater· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Perspectives on the Management of Oligometastatic Disease in Esophago-Gastric Cancer.
Thorsten Oliver Goetze, Salah-Eddin Al-Batran

Cancers (Basel)· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Systematic Review and Meta-Analysis on the Role of Perioperative Blood Transfusion in Patients Undergoing Radical Cystectomy for Urothelial Carcinoma.
Maxim Kochergin, Omar Fahmy, Lisa Esken, Thorsten Goetze, Evanguelos Xylinas

Bladder Cancer· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis